FENC - フェネック・ファ―マシュ―ティカルズ （Fennec Pharmaceuticals Inc.）

After a long approval process, with two CRL speed bumps, Fennec is finally a de-risked investment opportunity with substantial upside potential. Read more here.

Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) – Analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Tuesday, April 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.49 per share for the year, down from […]

Fennec received FDA approval for Pedmark. The NCCN and the EMA have endorsed Pedmark, strengthening its market prospects. Read more on FENC stock here.

Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 116.35% from the stock’s […]

~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxicity and a Favorable Benefit-Risk Profile With Pedmarqsi~ ~ Pedmarqsi is Currently Marketed as PEDMARK in

The following slide deck was published by Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company focused on the development of PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric… | November 14, 2022

Fennec Pharmaceuticals press release (FENC): Q3 GAAP EPS of -$0.31 misses by $0.13.Cash and cash equivalents of $29.75M.“This was an important quarter for Fennec with the FDA approval…

~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing of resubmitted New Drug Application (NDA) for PEDMARK TM (sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than 18 years of age with localized, non-metastatic, solid tumors. The … Full story available on Benzinga.com

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM

Fennec Pharmaceuticals (FENC) resubmitted an application to the U.S